Under a tenth of individuals eligible to benefit from weight-loss injections including Wegovy have access to them, caution the World Health Organization as it publishes its first recommendations on the therapies.
Given in excess of 1,000,000,000 people worldwide now living with obesity, it is urging broader and more equitable availability to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.
"Our latest guidelines acknowledges that excess weight is a chronic disease that can be treated with holistic and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are major obstacles to widespread availability to the jabs that can help people shift significant body mass, notes the organization.
Skinny Jab Supply Crisis
Even in the current most favorable case, the production of GLP-1 therapies could only cover around 100 million people – under 10% of eligible patients, per the health organization.
The guideline calls on nations and manufacturers to widen access, via strategies such as licensing agreements.
A patent on semaglutide – the main component of a leading brand – is set to lapse in a number of nations in 2026.
How Obesity Drugs Operate
These medications imitate a natural hormone to reduce digestion speed, suppress the appetite and enhance the sense of being full so people consume fewer calories.
Individuals typically begin shedding pounds after several weeks of beginning the weekly injections.
Studies suggests patients may regain a significant portion after a year of stopping the medication, as their typical hunger come back.
To be carrying excess weight elevates your likelihood for developing health problems, like diabetes, heart disease, stroke, and certain cancers.
Obesity affects people in all nations and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
